reports
Staar Surgical Co: 1 director
A director at Staar Surgical Co bought 1,315 shares at 37.990USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
STAAR Surgical Reports Second Quarter 2024 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024. Second Quarter 2024 Overview Net sales up 7% to $99.0 million and up 9% to $100.4 million in constant currency ICL sales up 7% to $99.4 million and units up 3% Gross margin at 79.2% vs. 76.6% year ago Net income of $7.4 million or $0.15 per share vs. net income of $6.1 million or $0...
STAAR Surgical to Report Second Quarter Results on August 7, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern...
STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth ...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Canaccord Genuity 44th Annual Growth Conference, which will be held in Boston, Massachusetts. Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. Eastern T...
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Heal...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida. Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Wednesday, June 12, 2024, at 8:00 a.m. Eastern T...
STAAR Surgical Reports First Quarter 2024 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview Net sales up 5% to $77.4 million and up 7% in constant currency ICL sales up 9% and units up 2% Gross margin at 78.9% vs. 78.3% year ago Net loss of $3.3 million or $0.07 loss per share vs. net income of $2.7 million or $0.05 income per share year ago Adj...
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America. This press release features multimedia. View the full release here: Tom Frinzi, Chair of the Board, Presi...
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy ...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO. This press release features multimedia. View the full release here: Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business ...
STAAR Surgical to Report First Quarter Results on May 7, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close. STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for d...
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company obtained U.S. FDA approval of the EVO ICL in March 2022. The Company is providing this informatio...
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meetin...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters...
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1 This press release features multimedia. View the full release here: (Graphic: STAAR Surgical) “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens mile...
- Jonathan Moreland
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. “Art Butcher and Wei Jiang are seasoned executives with broad leadershi...
STAAR Surgical to Participate in Two Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti Small Cap Conference, Wednesday, March 13 Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20. Investor pa...
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year ended December 29, 2023. Fourth Quarter 2023 Overview Net sales up 19% to $76.3 million in the fourth quarter ICL sales up 22% to $74.6 million and ICL units up 19% Gross margin at 79.6% vs. 77.7% year ago Net income of $7.8 million vs. $6.8 million year ago Earnings per share of $0.1...
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 877...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
CODI COMPASS DIVERSIFIED HOLDINGS
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
RLMD RELMADA THERAPEUTICS
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CLF CLIFFS NATURAL RESOURCES INC.
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
RCUS ARCUS BIOSCIENCES
AKTS AKOUSTIS TECHNOLOGIES INC
TLRY TILRAY
PAYS PAYSIGN INC
FBIO FABIEN CORP
ACET ADICET BIO INC
GRPN GROUPON INC.
VRDN VIRIDIAN THERAPEUTICS INC
AGL AGILON HEALTH
TBBK INC.
MPA THE BANCORP
SLDB INC.
COLB BLACKROCK MUNIYIELD PENNSYLVANIA FD
CRBP SOLID BIOSCIENCES INC
LSXMK COLUMBIA BANKING SYSTEM
INC.
CORBUS PHARMACEUTICALS HOLDINGS INC.
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
FDX FEDEX CORPORATION
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
FIZZ NATIONAL BEVERAGE CORP.
FBK FB FINANCIAL CORPORATION
PKTX PROTOKINETIX INC
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
ACET FABIEN CORP
GRPN ADICET BIO INC
HPK GROUPON INC.
ATHA HIGHPEAK ENERGY INC (A)
VRDN ATHIRA PHARMA
AGL VIRIDIAN THERAPEUTICS INC
MPA AGILON HEALTH
SLDB INC.
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and Austin, today announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses. This press release features multimedia. View the full release here: Dr. Matthew Sharpe, SharpeVision (Photo: Business Wire) STAAR...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.